AIM IMMUNOTECH INC. Proceeds from Issuance or Sale of Equity
AIM IMMUNOTECH INC. (AIM) reported Proceeds from Issuance or Sale of Equity of $367.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-17.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2026-08-07
- AIM IMMUNOTECH INC. proceeds from issuance or sale of equity for the quarter ending 2025-09-30 was -$398.00K, a 10050.00% decline year-over-year.
- AIM IMMUNOTECH INC. proceeds from issuance or sale of equity for the quarter ending 2025-06-30 was $105.00K, a 80.08% decline year-over-year.
- AIM IMMUNOTECH INC. proceeds from issuance or sale of equity for the quarter ending 2025-03-31 was $660.00K, a 100.61% increase year-over-year.
- AIM IMMUNOTECH INC. proceeds from issuance or sale of equity for the quarter ending 2024-12-31 was $32.00K, a 78.23% decline year-over-year.
- AIM IMMUNOTECH INC. proceeds from issuance or sale of equity for fiscal 2024 was $892.00K, a 83.92% increase from fiscal 2023.
- AIM IMMUNOTECH INC. proceeds from issuance or sale of equity for fiscal 2023 was $485.00K, a 506.25% increase from fiscal 2022.
- AIM IMMUNOTECH INC. proceeds from issuance or sale of equity for fiscal 2022 was $80.00K, a 99.39% decline from fiscal 2021.
- AIM IMMUNOTECH INC. proceeds from issuance or sale of equity for fiscal 2021 was $13.04M.
| Period end | Proceeds from Issuance or Sale of Equity 0 month | Proceeds from Issuance or Sale of Equity 1 month | Proceeds from Issuance or Sale of Equity 1 month as first filed | Proceeds from Issuance or Sale of Equity 3 month | Proceeds from Issuance or Sale of Equity 6 month | Proceeds from Issuance or Sale of Equity 9 month | Proceeds from Issuance or Sale of Equity 12 month |
|---|---|---|---|---|---|---|---|
| 2025-09-30 | -$398.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | -$293.00K derived: sum of 2 quarters · filed 2025-11-17 | $367.00K 10-Q · filed 2025-11-17 | $399.00K derived: sum of 4 quarters · filed 2025-11-17 | |||
| 2025-06-30 | $105.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $765.00K 10-Q · filed 2025-08-14 | $797.00K derived: sum of 3 quarters · filed 2025-08-14 | $801.00K derived: sum of 4 quarters · filed 2025-11-17 | |||
| 2025-03-31 | $660.00K 10-Q · filed 2025-05-15 | $692.00K derived: sum of 2 quarters · filed 2025-05-15 | $696.00K derived: sum of 3 quarters · filed 2025-11-17 | $1.22M derived: sum of 4 quarters · filed 2025-11-17 | |||
| 2024-12-31 | $32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $36.00K derived: sum of 2 quarters · filed 2025-11-17 | $563.00K derived: sum of 3 quarters · filed 2025-11-17 | $892.00K 10-K · filed 2025-03-27 | |||
| 2024-09-30 | $1.30M 10-Q · filed 2026-08-07 | $1.26M 10-K · filed 2025-03-27 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | $531.00K derived: sum of 2 quarters · filed 2025-11-17 | $860.00K 10-Q · filed 2025-11-17 | $1.01M derived: sum of 4 quarters · filed 2025-11-17 | |
| 2024-06-30 | $527.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $856.00K 10-Q · filed 2025-08-14 | $1.00M derived: sum of 3 quarters · filed 2025-08-14 | $1.24M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $329.00K 10-Q · filed 2025-05-15 | $476.00K derived: sum of 2 quarters · filed 2025-05-15 | $709.00K derived: sum of 3 quarters · filed 2025-05-15 | $714.00K derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $147.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $380.00K derived: sum of 2 quarters · filed 2025-03-27 | $385.00K derived: sum of 3 quarters · filed 2025-03-27 | $485.00K 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $233.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $238.00K derived: sum of 2 quarters · filed 2024-11-14 | $338.00K 10-Q · filed 2024-11-14 | $338.00K derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $105.00K 10-Q · filed 2024-08-14 | $105.00K derived: sum of 3 quarters · filed 2024-08-14 | $130.00K derived: sum of 4 quarters · filed 2024-08-14 | |||
| 2023-03-31 | $100.00K 10-Q · filed 2024-05-15 | $100.00K derived: sum of 2 quarters · filed 2024-05-15 | $125.00K derived: sum of 3 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $25.00K derived: sum of 2 quarters · filed 2024-04-01 | $80.00K 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | $25.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $80.00K 10-Q · filed 2023-11-14 | |||||
| 2022-06-30 | $55.00K 10-Q · filed 2023-08-14 | ||||||
| 2021-12-31 | $125.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $13.04M 10-K · filed 2023-03-31 | |||||
| 2021-09-30 | $12.92M 10-Q · filed 2022-11-14 | ||||||
| 2018-06-30 | $4.76M 10-Q · filed 2018-08-14 | ||||||
| 2018-03-24 | $475.00K 10-K · filed 2020-03-30 | ||||||
| 2017-07-10 | $65.00K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |